SCHEMBL1816941

SCHEMBL1816941

Cc1ccc(S(=O)(=O)N2CCOc3ccc(-c4csc(C#N)c4)cc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 1/20 0.53
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ PKM P14618 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ CPT1A P50416 3/20 0.40
▸ CPT1B Q92523 3/20 0.40
▸ CYP11B1 P15538 1/20 0.39
▸ CYP11B2 P19099 1/20 0.39
▸ PKLR P30613 1/20 0.38
▸ PDE3B Q13370 2/20 0.38
▸ PDE3A Q14432 2/20 0.38
▸ RORC P51449 1/20 0.38
▸ NR1H2 P55055 1/20 0.38
▸ NR1H3 Q13133 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1819206 0.90 PKM (0.42) CYP2C9KMT2AMEN1PKMNPC1
SCHEMBL1817593 0.90 NR1H3 (0.46) CYP2C9KMT2AMEN1PKMNPC1
SCHEMBL1817317 0.89 CYP2C9 (0.44) CYP2C9KMT2AMEN1PKMMAPT
SCHEMBL1819614 0.89 NPC1 (0.57) CYP2C9KMT2AMEN1PKMMAPT
SCHEMBL1817603 0.89 CYP2C9 (0.42) CYP2C9KMT2AMEN1PKMMAPT
SCHEMBL1821637 0.89 PKM (0.48) CYP2C9KMT2AMEN1PKMNPC1
SCHEMBL1818601 0.85 CYP2C9 (0.57) CYP2C9KMT2AMEN1PKMMAPT
SCHEMBL1818674 0.84 CYP2C9 (0.53) CYP2C9KMT2AMEN1PKMMAPT
SCHEMBL12818380 0.84 LMNA (0.42) CYP2C9KMT2AMEN1PKMMAPT
SCHEMBL12817769 0.84 CYP2C9 (0.38) CYP2C9KMT2AMEN1PKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011057892-A1 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES ELARA PHARMACEUTICALS GMBH (DE) 2011-05-19 — — WO claimed
WO-2011057892-A1 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES ELARA PHARMACEUTICALS GMBH (DE) 2011-05-19 — — WO disclosed
Send feedback